Exabis Library
Welcome to the e-CCO Library!
P593: A national database study on colectomy and colorectal cancer in ulcerative colitis: what is the role of appendectomy?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P593: Biologicals and small molecule combotherapies: promising experience in refractory IBD patients
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P593: Efficacy, tolerance and safety of low-volume bowel preparations in inflammatory bowel diseases: Results from a French national multicentre study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P593: Hospital resource use and cost associated with first-line anti-TNF therapy in patients with IBD in the UK: comparison of subcutaneous (adalimumab) and intravenous (infliximab) therapies
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P593: Impact of immunomodulating treatment modalities, active smoking and (repeated) COVID19 vaccination on S-antibody seroconversion in IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P593: Ustekinumab for the treatment of perianal Crohn’s disease. A real-world experience in a Spanish hospital
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P594 Increased levels of stress, anxiety and depression among patients with CD and UC
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P594: Bowel ultrasound is useful in predicting relapse in patients with Ulcerative Colitis in remission
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P594: Patient-reported outcomes in pain and discharge correlate with objective assessments of perianal fistula remission in Crohn’s disease (CD)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P594: Predictors of non-response to repeated faecal microbiota transplantation in patients with therapy refractory ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P594: Ustekinumab treatment effectiveness in clinical practice – a multicentre retrospective review of long-term outcomes in Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P594: Utilisation of anti-TNF agents in phlegmonous Crohn’s disease: an Australian tertiary referral centre experience
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P594: Vedolizumab dose intensification does not always improve treatment persistence.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P595 Feasibility and performance of a fully automated endoscopic disease severity grading tool for ulcerative colitis using unaltered multisite videos
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P595: Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD–GO-SWIBREG
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P595: Early medical therapy and risk of subsequent perianal fistula development among paediatric patients with Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P595: Finding predictors of azathioprine-induced pancreatitis in patients with inflammatory bowel disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P595: The influence of vitamin D on expression of cytokines mRNA in IBD
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P595: Time of Therapeutic Drug Monitoring of infliximab during induction and its relationship with clinical remission in Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P595: Validation of a predictive algorithm for thiopurine induced hepatotoxicity in IBD patients
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM